PAS 2017: Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection

alt

More than half of children treated with immunosuppressive drugs for gastrointestinal or rheumatological conditions no longer had protective levels of antibodies against hepatitis B virus (HBV) and may require repeat vaccinations, according to a study presented at the Pediatric Academic Societies Meeting last week in San Francisco.

Children with inflammatory bowel disease (IBD), juvenile arthritis, and other autoimmune conditions are often treated with biologic therapy. While these drugs have transformed management of chronic inflammatory conditions, they can increase the risk of infections, lead to reactivation of chronic viral infections, and potentially accelerate the decline of antibody levels in people who have been vaccinated.

HBV reactivation can cause severe hepatitis flares, and the Advisory Committee on Immunization Practices recommends that patients starting immunosuppressive therapy be screened for serological markers of hepatitis B immunity and revaccinated if necessary. But this has not been well studied in children.

Emily Smitherman from Cincinnati Children's Hospital and colleagues retrospectively analyzed hepatitis B serology results from 315 pediatric gastroenterology and rheumatology patients who received intravenous biologic therapy between October 2015 and June 2016.

The mean age of the patients was approximately 17 years. A majority had IBD and used tumor necrosis factor (TNF) inhibitors such as infliximab (Remicade). A third had various rheumatological conditions, mainly juvenile idiopathic arthritis, and were treated with TNF inhibitors or other biologics including anti-IL6, anti-T-cell, or anti-B-cell agents.

Results

Over half of the children who were found to be non-immune were given repeat HBV vaccinations. Among those with complete post-vaccine serology results, 68% tested positive for HBsAb, indicating they had regained protection. This showed that a majority of patients can still mount an immune response while on biologic therapy.

These study results raise the question of whether all children should be screened for sustained immunity to HBV, not only those receiving immunosuppressive therapy, Smitherman suggested.

5/16/17

Source

E Smitherman, L Favier, N Aljaberi, et al. Waning hepatitis B immunity status in a significant proportion of immunocompromised pediatric rheumatology and gastroenterology patients. Pediatric Academic Societies Meeting. San Francisco, May 6-9, 2017. Abstract 1670.1.